Our New Profile is: PSID
WE HAVE PROFILED PSID 3 TIMES AND THE RESULTS HAVE BEEN 3 MASSIVE RUNS.
Run 1: .0177 to .04 Overnight on Aug 7 for 130%
Run 2: .0185 to .025 Overnight on Aug 16 for 35%
Run 3: .015 to .041 From Aug 22 to Sept. 15 for 127%
The company just did a huge reverse split back in May, wiping out the float and leaving this one trading thin with a tiny market cap of roughly $700,000
Good Evening Everyone,
Today’s profile traded great and looks like it is building a base right here. It closed green and looks very solid moving forward. Continue to watch it.
We are putting PSID back on the radar.
I ask that you go back through your records and see how well we have done with this one.
PSID has been a tremendous winner for us 3 times in the recent past.
Twice we have seen this one run triple digits in a fairly short amount of time.
Right now it is sitting at .0167 which seems to be a sweet spot for this one. This has launched from under .02 countless times since it has reversed back in May.
You have to check out the recent news on this one. Since we last looked at it, PSID has put out several encouraging news announcements.
The latest came today which highlighted the 3rd quarter.
******BREAKING NEWS JUST OUT TODAY******
PositiveID Announces Highlights for the Third Quarter of 2017
DELRAY BEACH, Fla., Oct. 09, 2017 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, today announced highlights for the third quarter of 2017. The Company intends to announce its financial results for the third quarter ended September 30, 2017, in mid-November.
- PositiveID’s ExcitePCR subsidiary successfully detected Ebola virus on its FireflyDX™ breadboard pathogen detection system and published a white paper and data.
- ExcitePCR subsidiary announced the FireflyDX-Portable™, a lightweight, realtime pathogen detection system under development, designed to deliver on-site, biological results in less than 30 minutes, including sample preparation time, with commercial availability scheduled for late 2018.
- ExcitePCR’s CEO Lyle L. Probst was a featured panelist on a three-person BioWatch Panel discussion held at the National Academies of Sciences, Engineering, and Medicine.
- ExcitePCR announced its Board of Advisors, with industry expertise ranging from biodefense and molecular diagnostics to agricultural genomics and infectious diseases.
- PositiveID’s E-N-G Mobile Systems (“ENG”) subsidiary year-to-date vehicle bookings at the end of the third quarter of 2017 increased 152% compared to the first nine months of 2016; this increase was driven by bookings during the third quarter of more than $1.5 million.
- The Company’s Thermomedics subsidiary continued marketing activities to prepare for the commercial launch of the Bluetooth®-enabled version of its Caregiver® non-contact thermometer.
We expect to see a lot of action at the bell. This one is pretty liquid and has a big following. PSID has been somewhat of a “Cult” stock over the years.
Late last month they announced today that its E-N-G Mobile Systems (“ENG”) subsidiary bookings for the first half of 2017 increased 158% from the first half of 2016 to $2.4 million. ENG is a specialty vehicle manufacturer, which has delivered more than 1,500 vehicles, with a focus on building customized mobile laboratories.
PositiveID Corporation™ (OTCQB: PSID) is a life sciences tools and diagnostics company specializing in biological detection and molecular diagnostic systems for America’s homeland defense and the global healthcare market. PositiveID specializes in the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its ExcitePCR subsidiary. PositiveID is also a leader in the mobile technology vehicle market through its E-N-G Mobile Systems subsidiary.
PositiveID Successfully Detects Ebola Virus on its Firefly Dx Prototype System
Aug 08, 2017
DELRAY BEACH, Fla., Aug. 08, 2017 (GLOBE NEWSWIRE) — PositiveID Corporation (OTCQB:PSID), a life sciences company focused on detection and diagnostics, and its ExcitePCR Corporation subsidiary announced today that it has successfully detected Ebola virus on the Firefly Dx breadboard pathogen detection system (“prototype system”) and published a white paper and data on PositiveID’s website and ExcitePCR’s website.
In a collaborated effort with assay partner GenArraytion Inc., ExcitePCR successfully detected Ebola virus on the Firefly Dx prototype system. Ebola virus was tested at low number of copies via polymerase chain reaction (PCR) and the amplification curves demonstrated a cycle threshold (Ct) of 21. The automated runs successfully synthesized cDNA using a proprietary reverse transcriptase (RT) step and then completed a 40-cycle PCR to produce the results.
Rapid detection and diagnosis of Ebola virus infection along with vaccination is imperative to quickly containing an epidemic. Ebola is an RNA virus and requires a RT step prior to PCR. Despite its potential diagnostic advantages, RT-PCR methodology (both conventional and real-time approaches) typically requires significant laboratory infrastructure, electrical power, multiple temperature-sensitive reagents, the operation and maintenance of specialized equipment, and technical expertise in molecular biology, potentially complicating deployment in resource-limited settings.
“At the height of the Ebola virus outbreak, there were multiple challenges with accurately diagnosing individuals due to the need to collect samples, take them back to a central lab, and then wait hours or even days for results,” stated Lyle L. Probst CEO and President of ExcitePCR. “Firefly Dx could eliminate those challenges as a self-contained, portable lab for point-of-care/point-of-need applications, providing results in 30 minutes.”
The recent outbreak of Ebola virus disease in West Africa has highlighted both the importance of rapid and accurate diagnosis of this disease and the challenges around diagnostic testing. Throughout the 2014-2015 outbreak, diagnosis relied primarily on testing of venipuncture blood samples from symptomatic individuals in a biocontainment laboratory facility, leading to challenges with specimen collection and data management and often a prolonged turnaround time to final results.
Continued Mr. Probst, “Ebola detection is a perfect example of an application where Firefly Dx could be particularly critical – in remote locations, far from lab facilities, where time to results can mean life or death. This is why we have formed ExcitePCR; to facilitate getting the necessary strategic partner and direct funding in place to complete the development of what we believe is a very important product that can change the face of biological detection.”
In addition to Ebola virus, the Firefly Dx prototype system has also successfully detected a number of other pathogenic organisms including Zika, E. coli, influenza, MRSA, MSSA, C. diff and others.
The Company’s core technology is used for airborne pathogen detection, rapid biological diagnostics and sample preparation applications.
The bio-detection market has seen significant growth over the past decade due to incidents involving Anthrax, ricin, SARS, various strains of influenza, Ebola and other biological weapons. These events have confirmed that threats of infectious disease and bioterrorism are persistent and real.
With expansive foreign troop deployment, increasing domestic populations, and the need for a stable supportive agricultural infrastructure, the availability of effective molecular screening technologies is of growing importance. Whether natural or man-made, an invasive disease outbreak without proper monitoring or detection, and thus resulting in reduced countermeasure effectiveness, can significantly affect the health and commercial stability of livestock or human populations on a large scale. To this end, many biological and chemical-based methodologies exist to detect a wide range of potential pathogenic threats. Unfortunately, currently available technologies are still costly, labor intensive, and often limited to laboratory/clinical settings, thus falling short of truly effective point-of-need or timely site-specific monitoring.
PositiveID offers solutions for bio-threat detection in the field (whether indoors or outdoors), at the point of need.
PositiveID develops biological detection and diagnostics systems, including its M-BAND and Firefly Dx systems, which use real-time polymerase chain reaction (PCR) chemistry. PCR amplifies a sample’s DNA and copies it billions of times. PCR is used every day to diagnose diseases, identify bacteria and viruses, and for many other applications. With real-time PCR, the amplification of the DNA can be measured as it occurs, thereby speeding up the ability to deliver results. Real-time PCR is one of the most sensitive and specific bio-detection capabilities available today.
A critical and highly complicated step prior to performing real-time PCR is sample preparation. PositiveID’s patented sample prep technologies use ultrasonic lysis for the rupture of tough cellular membranes. The lysed sample is then microfluidically passed through a purification apparatus that isolates and purifies nucleic acid. The Company’s expertise in sample prep is reflected by its strong intellectual property position.
The Company began developing complex microfluidic systems to perform sample processing and purification for the Defense Advanced Projects Agency (DARPA). It then developed a similar system, including a thermal cycler for polymerase chain reaction (PCR) analysis for the US Army’s Edgewood Chemical and Biological Command (ECBC).
PositiveID’s microfluidic technology replaces robotics with integrated microfluidics, reducing cost and increasing reliability. Its microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed, automated system. The embedded devices perform cell lysis (including difficult spores) in less than one minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.
The Caregiver® thermometer by Thermomedics Inc. is the world’s first non-contact device with TouchFree™ technology developed by the team that invented tympanic thermometry! THE CAREGIVER® PROFESSIONAL is a clinical-grade infrared thermometer for measurement of forehead temperature in adults, children, and infants without contact. It is designed for use in a wide variation of medical settings and can also deliver ambient/skin surface temperatures with the flick of a switch.
PositiveID develops biological detection and diagnostics systems, including its M-BAND and Firefly Dx technologies. The Company began developing complex microfluidic systems to perform sample processing and purification for the Defense Advanced Projects Agency (DARPA). It then developed a similar system, including a thermal cycler for polymerase chain reaction (PCR) analysis for the US Army’s Edgewood Chemical and Biological Command (ECBC). PositiveID’s microfluidic technology replaces robotics and manual processes used in existing systems with integrated microfluidics in a closed, automated system, which reduces cost, increases reliability and enhances the effectiveness of sample processing.
PositiveID is focused primarily on its M-BAND airborne biot-threat detector, which was developed under contract with the U.S. Department of Homeland Security (“DHS”) Science & Technology directorate, and its Firefly Dx system, which is designed to deliver molecular diagnostic results from a sample in less than 30 minutes at the point-of-need, using a portable, handheld system.
The Company’s M-BAND detection system continuously and autonomously analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up-to-date status of field conditions. M-BAND performs high specificity detection for up to six organisms on the Centers for Disease Control’s category A and B select agents list.
The goal of the Company’s Firefly Dx is to enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems. Firefly is being developed further for a broad range of biological detection situations for applications including military, agricultural and healthcare. The system has already demonstrated the ability to detect and identify other common pathogens and diseases such as various strains of influenza, E. coli, methicillin-resistant staphylococcus aureus (“MRSA”) and human papilloma virus (“HPV”).
The Caregiver® thermometer by Thermomedics, Inc. is the world’s first non-contact device with TouchFree™ technology developed by the team that invented tympanic thermometry. CAREGIVER® is a clinical-grade infrared thermometer for measurement of forehead temperature in adults, children, and infants without contact. It is designed for use in a wide
variation of medical settings and can also deliver ambient/skin surface temperatures with the flick of a switch. Learn more about PositiveID’s Caregiver thermometer.
Mobile Technology Vehicles
PositiveID’s wholly owned subsidiary, E-N-G Mobile Labs, provides specialty vehicle manufacturing for TV news vans and trucks, emergency response trailers, mobile command centers, mobile labs, and other special purpose vehicles. E-N-G is a leading U.S. manufacturer of specialized vehicles that are field friendly and field tough. Major
applications include mobile TV broadcasting, microwave and satellite uplink trucks, emergency response vehicles, communications command and control, surveillance vans, mobile environmental, medical, dental, and health laboratories and clinics, mobile cellular phone vehicles, infrared testing, and many other applications. We also provide mobile analytical triage centers to insulate central labs from pandemic outbreaks.
PositiveID historically has worked with large government and commercial partners such as the Department of Homeland Security to develop and manufacture its products. The Company’s M-BAND product was developed with $30 million of contract funding under the DHS’ BAND program.
The Company continues to work with DHS and is also currently working the Department of Defense, NASA, U.S. Special Operations Command, and well as several high profile government contractors.
PositiveID has an exclusive license and a teaming agreement with The Boeing Company, wherein Boeing was granted the exclusive right to distribute M-BAND units in North America, and PositiveID became the exclusive provider of reagents and assays to Boeing.
OTC Disclosure & News Service
Make sure you start your research. We will have more info shortly.
Disclaimer – This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell sec_urities. This newsletter is owned, operated and edited by Archangel Media Consulting, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “Archangel Media” refers to Archangel Media Consulting, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give invest_ment recommendations. Always do your own research and consult with a licensed invest_ment professional before invest_ing. This communication is never to be used as the basis of making invest_ment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per sh_are are speculative and carry a high degree of risk, so only inv_est what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the sec_urities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on sh_are prices. If we own any sh_ares we will list the information relevant to the stock and number of sh_ares here. We have been compensated a fee of seven thousand usd by a third party, South Shore Marketing, llc for a 2 day awareness campaign regarding PSID. We have been compensated a total of fifteen thousand dollars this month regarding PSID by the same third party, South Shore Marketing, LLC Archangel Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate sh_ares of the profiled company at or near the time you receive this communication, which has the potential to hurt sh_are prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and sh_are price during the course of inves_tor relations marketing, which may end as soon as the inves_tor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and sh_are price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Archangel Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.